Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D.
Business Of Biotech
00:00
The Mechanics of the Acquisition
With so many small biotechs being devalued, I think there's optimism that there'll be a lot of M&A activity in this coming year. And you should know today, I learned that FSA may, which is a regulator in Belgium, they say if it is fine that we get onto the market. So I'm going to ask you to just sort of take us behind the scenes of the mechanics of the deal and what a fellow small bio pharma CEO might expect from the experience.
Transcript
Play full episode
